Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Review Division At The Head Of The Pack – But Can The Others Keep Up?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Analysis of drug review performance by division finds Cardiovascular & Renal Drugs Division to occupy the lower end of the spectrum. Staffing appears to be a vital component of review performance, giving weight to the researchers’ warning of impending wholesale staff turnover.

Advertisement

Related Content

BIO Survey Seeks To Uncover Inconsistencies In Review Divisions
Lagging CDER Review Divisions Could Learn From Oncology, Antiviral Offices
Are The 90s Back? Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
FDA/EMA Review Discord: Is Europe Slow On Oncology, Or Just Fast On Everything Else?
Synchronized Regulation: Tandem Approvals Of Xalkori, Diagnostic Required Considerable Coordination
Biosimilars, Generic Programs Leave Little Room For Other New FDA Drug Initiatives In FY ‘13
Innovative Drug Development: Kalydeco Provides A Paradigm, FDA’s Spielberg Says
FDA Approving More Novel Drugs Without Advisory Committee Review
Fast Track Speeds Approval, Tufts Finds; Therapeutic Category Also Key

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel